India's Resilience Amid Trump's Tariff Turmoil: A Focus on Generic Drugs

India remains insulated from US's new 100% tariffs on patented drugs due to its strong foothold in exporting low-cost generics to America. This strategic market position keeps the nation shielded from immediate impacts. Future uncertainties loom for Indian innovators as global trade dynamics continue to evolve.

India's pharmaceutical sector seems largely unaffected by US President Donald Trump's recent announcement of imposing 100% tariffs on certain patented drugs. According to the Global Trade Research Initiative (GTRI), India's primary export of low-cost generic medicines to the US safeguards it from considerable impact.

The tariffs, directed at patented pharmaceuticals, stem from a national security-focused Section 232 investigation. Despite the US's aggressive trade strategies, generic medicines, making up over 90% of the drugs used in the US, remain exempt to prevent shortages and price spikes.

However, concerns persist for Indian firms producing branded or specialty drugs and supplying inputs for patented medicines, which might confront tariff pressures. The broader apprehension lies in the potential future inclusion of generics in the tariff ambit, which would drastically alter the current trade landscape.

(With inputs from agencies.)